Technology ID
TAB-4482

ApoE-ApoCII Chimeric Peptides for Treating Hypertriglyceridemia

E-Numbers
E-055-2019-0
Lead Inventor
Ghosh, Soumitra
Lead IC
NHLBI
Co-Inventors
Lo, Chih-Hung (Larry)
Remaley, Alan
Sviridov, Denis
Wolska, Anna
Devalaraja, Madhav (Matt)
ICs
NHLBI
Applications
Therapeutics
Research Materials
Therapeutic Areas
Cardiology
Development Stages
Pre-clinical (in vivo)

This technology includes apoE-apoCII chimeric peptides that possess the ability to lower the triglyceride level both in vitro and in vivo. These peptides can be used for treating hypertriglyceridemia and alleviating other diseases and conditions associated with increased triglycerides.

Commercial Applications
Treatment for hypertriglyceridemia.

Competitive Advantages
The peptide sequence is novel and is the first example of an apoC-11 mimetic peptide that contains an additional motif based on ApoE that enhances removal of triglyceride-rich lipoproteins.

Request More Info

Licensing Contact:
Shmilovich, Michael
[email protected]

Patents

  • US
    Provisional (PRV) 62/700,751
    Filed on 2018-07-19
    Status: Abandoned

Collaborations

  • Materials Available
  • Licensing

Collaboration Description

  • We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology.
Date Published